BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionFmr Llc
Latest Disclosed Ownership2,343,754 shares
Latest Disclosed Value $ 174,047,182
Fmr Llc reports 1.95% decrease in ownership of BBIO / BridgeBio Pharma, Inc.

On May 15, 2026 - Fmr Llc filed a 13F-HR form disclosing ownership of 2,343,754 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $174,047,172 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 2,390,362 shares of BridgeBio Pharma, Inc.. This represents a change in shares of -1.95% during the quarter. The current value of the position is $153,469,012 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,343,754 -46,608 -1.95 174,047 -4.81 0.0018
2026-02-17 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,390,362 689,615 40.55 182,839 106.98 0.0093
2025-11-13 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,700,747 -326,648 -16.11 88,337 0.91 0.0046
2025-08-14 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 2,027,395 -148,404 -6.82 87,543 16.39 0.0049
2025-05-12 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,175,799 554,204 34.18 75,217 69.04 0.0048
2025-02-13 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,621,595 -198,727 -10.92 44,497 -3.99 0.0027
2024-11-13 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,820,322 280,409 18.21 46,345 18.82 0.0028
2024-08-13 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,539,913 -785,699 -33.78 39,006 -45.76 0.0025
2024-05-13 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,325,612 -88,729 -3.68 71,908 -26.22 0.0048
2024-02-13 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,414,341 -13,181 -0.54 97,467 59.67 0.0075
2023-11-13 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 2,427,522 766,639 46.16 61,041 113.68 0.0053
2023-08-11 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,660,883 -443,351 -21.07 28,567 -18.12 0.0024
2023-08-11 2023-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 2,104,234 1,401,129 199.28 34,888 551.26 0.0032
2023-05-11 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,104,234 1,401,129 34,888 0.0006
2023-02-13 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 703,105 -280,244 -28.50 5,358 -45.19 0.0005
2022-11-10 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 983,349 2,987 0.30 9,774 9.80 0.0010
2022-08-12 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 980,362 3,165 0.32 8,902 -10.24 0.0009
2022-05-13 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 977,197 -204,839 -17.33 9,918 -49.70 0.0008
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,182,036 -506,114 -29.98 19,716 -75.08 0.0015
2022-02-14 2021-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,688,150 301,462 21.74 79,123 -6.40 0.0063
2021-11-15 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,688,150 301,462 79,123 0.0063
2021-08-13 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,386,688 -268,876 -16.24 84,532 -17.11 0.0066
2021-05-14 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,655,564 244,293 17.31 101,983 1.62 0.0087
2021-02-08 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,411,271 386,318 37.69 100,356 160.97 0.0089
2020-11-13 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,024,953 -523,943 -33.83 38,455 -23.87 0.0039
2020-08-24 2020-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,548,896 -78,356 -4.82 50,510 7.03 0.0056
2020-08-13 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,548,896 -78,356 50,510 1,240.8829
2020-05-14 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,627,252 -565,448 -25.79 47,191 -38.60 0.0065
2020-02-07 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,192,700 -444,438 -16.85 76,855 35.74 0.0085
2019-11-13 2019-09-30 13F BRIDGEBIO PHARMA COM 10806X102 2,637,138 -380,848 -12.62 56,619 -30.44 0.0068
2019-08-13 2019-06-30 13F BRIDGEBIO PHARMA COM 10806X102 3,017,986 3,017,986 81,395 0.0095
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.